Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead

Company Overview - Kodiak Sciences is a biotechnology company focused on developing innovative therapies for retinal diseases, leveraging advanced antibody biopolymer technology to address significant unmet medical needs in ophthalmology [6]. - The company has a pipeline led by KSI-301, which is currently in Phase IIb/III trials, along with preclinical candidates KSI-501 and KSI-601 [9]. Financial Performance - As of February 17, 2026, Kodiak Sciences had a market capitalization of $1.30 billion and a net income of -$217.34 million over the trailing twelve months [4]. - The company's stock price was $22.66, reflecting a 340% increase over the past year, significantly outperforming the S&P 500 [8]. Recent Developments - Braidwell LP disclosed a new position in Kodiak Sciences, acquiring 2,072,788 shares valued at $57.96 million during the fourth quarter of 2025, which represents 1.85% of Braidwell's reportable assets under management [2][8]. - Kodiak Sciences ended the third quarter with $72 million in cash and reported a quarterly net loss of $61.5 million, attributed to increased R&D spending related to active Phase 3 trials [11]. Market Context - The global anti-VEGF market, which Kodiak targets, is estimated to be around $15 billion, with three late-stage programs expected to provide topline data in 2026 [10]. - The company's strategic focus on ophthalmologists and retina specialists positions it well within a growing market for treatments of retinal vascular and inflammatory diseases [9].